These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38513079)

  • 1. Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura.
    Yada N; Zhang Q; Bignotti A; Gralnek SH; Sosnovske D; Hogan K; Ye Z; Zheng L; Zheng XL
    Blood Adv; 2024 May; 8(10):2536-2551. PubMed ID: 38513079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.
    Yada N; Zhang Q; Bignotti A; Ye Z; Zheng XL
    Thromb Haemost; 2024 Aug; 124(8):725-738. PubMed ID: 38272066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 5. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP.
    Saito K; Sakai K; Kubo M; Azumi H; Hamamura A; Ochi S; Amagase H; Kunieda H; Ogawa Y; Yagi H; Matsumoto M
    Blood Adv; 2024 May; 8(9):2151-2159. PubMed ID: 38386976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era.
    Laganà A; Trisolini SM; Maglione R; Mahnaz SB; Imperatore S; Vitullo D; Capria S
    Blood Coagul Fibrinolysis; 2024 Jan; 35(1):37-42. PubMed ID: 37994623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
    Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
    Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
    Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
    J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
    Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
    J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
    Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
    Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
    Kühne L; Knöbl P; Eller K; Thaler J; Sperr WR; Gleixner K; Osterholt T; Kaufeld J; Menne J; Buxhofer-Ausch V; Mühlfeld A; Seelow E; Schreiber A; Todorova P; Cukoski S; Jabs WJ; Özcan F; Gäckler A; Schönfelder K; Seibert FS; Westhoff T; Schwenger V; Eichenauer DA; Völker LA; Brinkkoetter PT
    Blood; 2024 Oct; 144(14):1486-1495. PubMed ID: 38838300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
    Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura.
    Falter T; Rossmann H; de Waele L; Dekimpe C; von Auer C; Müller-Calleja N; Häuser F; Degreif A; Marandiuc D; Messmer X; Sprinzl M; Lackner KJ; Jurk K; Vanhoorelbeke K; Lämmle B
    Blood Adv; 2023 Sep; 7(17):5091-5102. PubMed ID: 37399489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
    Coppo P; Joly BS;
    Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
    Miyakawa Y; Imada K; Ichikawa S; Uchiyama H; Ueda Y; Yonezawa A; Fujitani S; Ogawa Y; Matsushita T; Asakura H; Nishio K; Suzuki K; Hashimoto Y; Murakami H; Tahara S; Tanaka T; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):366-377. PubMed ID: 36427162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.